cancer

Study Finds Tanning Beds Raise Melanoma Risk Across The Body

Researchers found that tanning beds can cause serious DNA damage across almost all of the skin, helping explain why they sharply raise the risk of melanoma, the deadliest form of skin cancer. Dr Pedram Gerami, who leads a melanoma program at Northwestern University, noticed over many years that many...

FDA Proposes To Add Bemotrizinol As Sunscreen Active Ingredient

The U.S. Food and Drug Administration has announced that it is taking action to advance sunscreen innovation, part of a broader initiative in the Office of Nonprescription Drugs. The agency is proposing to add bemotrizinol as a permitted active ingredient for use in sunscreens. Based on the data...

Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of the treatment, when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute Myeloid Leukemia. The findings revealed...

BioNTech SE (BNTX) and Bristol-Myers Squibb Company (BMY), Tuesday announced the first interim data from a global randomized Phase 2 trial, evaluating pumitamig in patients with locally advanced/metastatic triple-negative breast cancer. The trial evaluated pumitamig in two dose levels and in combination...

Self-Swab HPV Tests Now Approved For Cervical Cancer Screening, Expanding Options For Women

Cervical cancer screening in the United States is entering a new era as the American Cancer Society (ACS) has updated its guidelines to include self-swab HPV tests.

Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies, for the joint development of an AI-based cancer pathology diagnostic support program. Through this partnership, the companies...

Becton, Dickinson and Company (BDX), Monday the Conformite Europeenne or CE Marked BD Onclarity HPV Assay for the BD COR System and the BD Viper LT System have been accepted for the World Health Organization list of prequalified in vitro diagnostic products. This WHO pre-qualification marks an important...

Monday, Merus N.V. (MRUS) has entered into a global non-exclusive collaboration and license agreement regarding Halozyme Therapeutics, Inc.'s ENHANZE drug delivery technology. Under the collaboration, the company has licensed the technology for the development and potential commercialization of subcutaneous...

Study Suggests Ultra-Processed Foods Might Elevate Early Polyp Risk In Women

A new study found that women who eat a lot of ultra-processed foods (UPFs) are about 1.5 times more likely to develop pre-cancerous polyps before age 50 than women who eat healthier diets. "The vast majority of these polyps do not become bowel cancer. But at the same time, we know the vast majority...

Melanoma Emerging As Growing Threat To US Veterans, Warns Research Group

As the nation honors the service and sacrifice of America's veterans, the Melanoma Research Alliance is shining a light on an overlooked health crisis: the rapidly rising rates of melanoma among U.S. military personnel and veterans. Melanoma, the deadliest form of skin cancer, is already one of the...

Halozyme Therapeutics, Inc. (HALO), Friday announced that Johnson & Johnson has received U.S. Food and Drug Administration approval of a new indication for DARZALEX Faspro as a single agent treatment of adult patients with high-risk smoldering multiple myeloma. The approval is based on the findings...

Study Finds No Survival Benefit From Radiation In Intermediate-Risk Breast Cancer Patients

A new international study has found that radiation therapy did not improve 10-year survival rates for women with early-stage, intermediate-risk breast cancer. The SUPREMO trial (Selective Use of Postoperative Radiotherapy after Mastectomy), led by the University of Edinburgh, followed more than 1,600...

Tuesday, Incyte Corp. (INCY) signed an exclusive option agreement with Prelude Therapeutics Inc. focused on the latter's previously undisclosed mutant selective JAK2V617F JH2 inhibitor program in development for patients with myeloproliferative neoplasms. As per the terms of the deal, Incyte secures...

Exelixis, Inc. (EXEL), Monday announced data from STELLAR-303, evaluating zanzalintinib in combination with atezolizumab versus regorafenib for patients with metastatic colorectal cancer. The combination therapy improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and...

New Nanoparticle Vaccine Prevents Multiple Cancers In Mice, Study Finds

Scientists at the University of Massachusetts Amherst have developed a new nanoparticle-based vaccine that can prevent several aggressive cancers in mice, including melanoma, pancreatic cancer, and triple-negative breast cancer. In their experiments, up to 88 percent of vaccinated mice stayed cancer-free,...